- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe chronic plaque psoriasis
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 468KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 75KB)
Tildrakizumab – March 2023
Tildrakizumab: Injection 100 mg in 1 mL single dose pre-filled syringe; Ilumya®
Last updated
14 July 2023